Search This Blog

Thursday, April 9, 2020

BioCryst stock rallies on start of coronavirus drug study

BioCryst Pharmaceuticals Inc. BCRX, +3.50% shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, will be conducted in Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines.
https://www.marketwatch.com/story/biocryst-stock-rallies-on-start-of-coronavirus-drug-study-2020-04-09

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.